Skip to main content

Table 1 Patients characteristics at baseline

From: A first-in-human study investigating biodistribution, safety and recommended dose of a new radiolabeled MAb targeting FZD10 in metastatic synovial sarcoma patients

  Imaging Part Therapeutic Part
N = 20 N = 8
N (%) Arm A Arm B
N N
Number of Patients 20 3 5
Sex
 Men 10 (50.0%) 2 3
 Women 10 (50.0%) 1 2
Age at inclusion (years)
 Mean 42.1 31.0 41.4
 SD 13.68 10.44 13.59
 Median 43.0 26.0 43.0
 Range 21–67 24–43 21–57
PS (ECOG)
 0 8 (40.0%) 1 2
 1 10 (50.0%) 2 2
 2 2 (10.0%) 0 1
Primary tumor sites (at initial diagnosis)
 Upper limb 1 (5.0%) 0 1
 Lower limb 8 (40.0%) 2 2
 Trunck wall 5 (25.0%) 0 2
 Internal trunck 4 (20.0%) 0 0
 Head and neck 2 (10.0%) 1 0
Histological type
 Missing 1 0 1
 Spindle cell 14 (73.7%) 3 2
 Biphasic 2 (10.5%) 0 1
 Poorly differentiated 3 (15.8%) 0 1
Histological grade at initial diagnosis Grade 2 7 (35.0%) 3 2
Grade 3 13 (65.0%) 0 3
T T1 5 (25.0%) 0 2
  T2 14 (70.0%) 3 3
  TX 1 (5.0%) 0 0
N N0 19 (95.0%) 3 5
  N1 1 (5.0%) 0 0
M M0 20 (100%) 3 5
Tumor depth
 Superficial 3 (15.0%) 1 2
 Deep 17 (85.0%) 2 3
Disease status at inclusion
 Metastatic 18 (90.0%) 3 4
 Locally advanced 1 (5.0%) 0 1
 Both 1 (5.0%) 0 0
Surgery of the primary tumor
 Yes 18 (90%) 3 4
 No 2 (10%) 0 1
Prior Radiotherapy
 Yes 15 (75.0%) 3 3
 No 5 (25.0%) 0 2
Chemotherapy with Doxorubicin
 Yes, in monotherapy 5 (25.0%) 1 2
 Yes, associated 15 (75.0%) 2 3
Chromosomal translocation site
 missing 1 0 0
 SSX1 11 (57.9%) 1 4
 SSX2 5 (26.3%) 1 0
 Others 3 (15.8%) 1 1